Editorial
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2017; 23(33): 6009-6015
Published online Sep 7, 2017. doi: 10.3748/wjg.v23.i33.6009
Helminths as an alternative therapy for intestinal diseases
Aytan Miranda Sipahi, Daniel Machado Baptista
Aytan Miranda Sipahi, Daniel Machado Baptista, LIM 07-Laboratory of Experimental Clinical Gastroenterology, Department of Gastroenterology and Hepatology, Clínicas Hospital of University of São Paulo-HCFMUSP and, School of Medicine at the University of São Paulo, São Paulo 04023-062, Brazil
ORCID number: Daniel Machado Baptista (0000-0002-7790-4492).
Author contributions: Sipahi AM and Baptista DM contributed equally to this work.
Conflict-of-interest statement: Sipahi AM and Baptista DM declare no conflict of interest related to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Aytan Miranda Sipahi, MD, PhD, Professor of Medicine, Chief of Group of Intestinal Diseases, LIM 07-Laboratory of Experimental Clinical Gastroenterology, Department of Gastroenterology and Hepatology, Clínicas Hospital of University of São Paulo-HCFMUSP and, School of Medicine at the University of São Paulo, São Paulo 04023-062, Brazil. aytansipahi@gmail.com
Fax: +55-11-999398691
Received: April 12, 2017
Peer-review started: May 8, 2017
First decision: June 7, 2017
Revised: July 5, 2017
Accepted: August 9, 2017
Article in press: August 8, 2017
Published online: September 7, 2017

Abstract

Animal models and clinical studies have shown that helminth infections exert immunomodulatory activity, altering intestinal permeability and providing a potential beneficial action on autoimmune and inflammatory disorders in human beings, such as inflammatory bowel disease (IBD) and celiac disease. This is consistent with the theory that intestinal microbiota is responsible for shaping human immunological responses. With the arrival of the immunobiologic era and the use of antibodies, we propose a distinctive pathway for treating patients with IBD and celiac disease. We have some evidence about the safety and tolerability of helminth use, but evidence about their impact on disease activity is lacking. Using worms to treat diseases could be a possible way to lower treatment costs, since the era of immunobiologic agents is responsible for a significant rise in expenses. Some questions remain to be investigated regarding the use of helminths in intestinal disease, such as the importance of the specific species of helminths used, appropriate dosing regimens, optimal timing of treatment, the role of host genetics, diet, environment, and the elucidation of the exact mechanisms of action. One promising approach is the use of helminth-derived anti-inflammatory molecules as drugs. Yet there are still many challenges with this method, especially with regard to safety. Studies on intestinal permeability point to Strongyloides stercoralis as a useful nematode for these purposes.

Key Words: Helminths, Strongyloidiasis, Immunology, Inflammation, Inflammatory bowel diseases, Intestinal diseases, Intestinal permeability, Celiac disease

Core tip: Inflammatory bowel disease and celiac disease are immune-mediated pathologies that remain a treatment challenge for gastroenterologists. Despite the recent introduction of novel therapies, notably biological agents and newer management strategies, there are still many patients who do not respond, or have a poor response to current treatments. Helminth therapy seems a promising pathway to newer drugs, because it has been proven to alter intestinal permeability, altering the host’s immune response to a Type 2 cytokine-mediated response in animal models and pre-clinical studies. This editorial aims to stimulate further research in this field, hoping for better care for our patients.



INTRODUCTION

The intestinal epithelium functions as an important part of the digestion and absorption of fluids and nutrients. It also plays an immunologic role because it protects the host from environmental pathogens and antigens[1]. When this barrier is altered, it leads to ease of antigen entry and subsequently to immune stimulation and inflammation[2].

Many intestinal diseases have immunogenic components that alter intestinal permeability. Some pathologic processes increase intestinal permeability, such as inflammatory bowel disease (IBD)[3-11], atopic eczema[12], celiac disease, dermatitis herpetiformis[13], cystic fibrosis[14,15], alcohol consumption[16], use of nonsteroidal anti-inflammatory drugs[17-20], and acute infectious diarrhea[12,21]. In contrast, some infections, such as those caused by Blastocystis hominis[22], can decrease intestinal permeability and alter the barrier function of the epithelium. These may thus provide an alternative pathway for treating patients by deviating the host’s immunologic response.

Intestinal permeability can be measured in many ways. One is via measuring urinary clearance of radioactive chromium-51 labeled ethylenediaminetetraacetic acid (51Cr-EDTA). When urinary clearance of 51Cr-EDTA is decreased, this indicates decreased intestinal permeability. Werneck-Silva et al[23] demonstrated that infection with Strongyloides stercoralis can diminish intestinal permeability compared to healthy volunteers (P = 0.0001). Intestinal infection with S. stercoralis led to abnormalities in mucus secretion and intestinal motility, as well as possible loss of macromolecules. S. stercoralis is a soil-transmitted helminth and is one of the most common parasites that affects patients living in tropical areas[24]. It infects 100 to 200 million people worldwide[25]. It predominantly compromises the mucosa of the duodenum and upper jejunum, although the whole intestinal wall or more extensive segments of the intestine can be involved, especially in immunocompromised patients[26-28].

DISCUSSION
Hygiene hypothesis

The hygiene hypothesis was initially described in the 1970s. It suggests that the higher incidence of allergic diseases in predominantly urban white communities, compared to those rural and indigenous, is due to the less frequent viral, bacterial and helminth infections[29]. A decade later, Strachan proposed that reduced exposure to infections in early childhood, owing to a combination of diminished family size, improved living standards and higher levels of personal hygiene, might result in an increased risk of allergic disease later in life[30]. In addition to allergic disease[31-33], it is believed that the recent increase in other autoimmune and inflammatory disorders, especially in developed countries, could be explained by a similar hypothesis. Many factors may be involved, such as changes in intestinal microbiota during childhood[34].

Helminth infections, in specific intestinal worms, are a particular area of research interest, since they can modulate the host response, inducing immunologic tolerance. Aoyama et al[35] have demonstrated an inverse relationship between autoimmune liver diseases, such as primary biliary cirrhosis, autoimmune hepatitis, and primary sclerosing cholangitis, and S. stercoralis infection. Recent studies point to the negative effects of deworming, since the helminths are able to not only downregulate specific immune responses, but also to modulate autoimmune and allergic inflammatory responses, contributing to metabolic homeostasis[36]. The study on the use of helminths and their products as anti-inflammatory treatments is a growing field.

Helminth-induced immune responses

Parasitic helminths evolved with the mammalian immune system, promoting their own survival by altering host immune responses[37]. The immune response induced by these worms is dependent on a Type 2 cytokine response, involving the secretion of interleukin (IL)-4, IL-5, IL-9 and IL-13, accompanied by the activation of intestinal mast cells[38], eosinophils, goblet cells, enterocyte proliferation and intestinal contractility[39]. Granuloma formation then occurs, isolating the eggs and larvae, and inducing tissue repair[40]. Other accessory pathways are activated, including the upregulation of regulatory T cell and IL-10 and/or transforming growth factor beta levels, leading to a predominantly anti-inflammatory response. It has been shown that IL-10- deficient-mice with helminth infections have higher mortality and/or morbidity[41].

The role of CD4+ T cells in expressing Th1, Th2 and Th17 cytokines in human infection with S. stercoralis is better explored by Anuradha et al[42], who demonstrated a decrease in functional Th1 and Th17 cells and an increase in functional Th2 cells, compared to uninfected individuals. The regulation of Th1, Th2 and Th17 cells was predominantly dependent on IL-10, while the regulation of Th2 but not Th1 or Th17 cells was also dependent on TGFβ. Anuradha et al[43] also examined the circulating levels of cytokines in infected individuals (n = 32) compared to those uninfected, discovering significantly lower circulating levels of pro-inflammatory cytokines (gamma interferon, tumor necrosis factor alpha and IL-1) and significantly higher levels of anti-inflammatory cytokines (IL-4, IL-5, IL-9, IL-10, IL-13, IL-27, IL-37, and TGF-β). In addition, treatment of infection led to an opposite immunological response in the two studies. The question is whether these anti-inflammatory properties could be used in intestinal disorders with a predominant Type 1 cytokine response.

Helminth therapy for intestinal inflammation

The ability of helminth infections to alter and/or to suppress immune responses and intestinal inflammation could be useful in IBD[37]. To date, only two species of helminths have been used as clinical treatment: Trichuris suis, the pig whipworm, and Necator americanus, the human hookworm.

The first is acquired by ingestion of ova and colonization of the caecum and proximal colon of the human gut by worms, which only lasts a few weeks. The second infection develops after percutaneous administration of larvae that migrate to the small intestine, where they survive by feeding on blood from the mucosa. T. suis, due to the species-specificity and the lack of chronic infection, requires repeated treatments, although it poses lesser health issues. In the case of N. americanus, the long lasting infection means greater risk of anemia and gastrointestinal symptoms, which could be deleterious side effects[37]. To date, there are no studies of S. stercoralis for treating intestinal inflammation.

Evidence of helminth therapy in inflammatory bowel disease

Approximately 15 years ago, the first clinical studies of helminth therapy for intestinal disease in humans utilized embryonated viable eggs of T. suis in the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). These studies showed safety, tolerance and a significant disease remission when oral administration of viable and embryonated eggs was performed repeatedly[44,45]. A placebo–controlled, double-blind, randomized trial in UC patients significantly improved the disease activity index and showed no side effects, although the remission rate was not different than placebo[46]. Another double-blind, placebo-controlled, randomized study (NCT01434693) reported that a single dose of T. suis ova (TSO) up to 7500 ova was well tolerated and did not result in short- or long-term treatment-related side effects in CD patients[47].

A brief review of Clinicaltrials.gov reveals three interventional studies of TSO in CD and two in UC. In CD, the studies were sponsored by Coronado Biosciences, which changed its name to Fortress Biotech, and by Dr. Falk Pharma GmbH. TRUST-1 (NCT01576471), a Phase 2 clinical trial evaluating 250 North American patients with moderate-to-severe disease did not improve the disease activity index or remission rates, although a nonsignificant improvement was noted in patients with a more severe disease score.

TRUST-2 (NCT01279577), a double-blind, placebo-controlled, randomized trial of 252 European adults with mildly-to-moderately active ileocolonic, uncomplicated CD, documented that the administration of fortnightly doses of 250, 2500, or 7500 TSO/15 mL suspension/day over 12 wk, with a four-week follow-up, was safe, with no serious adverse drug reactions. There was a dose-dependent immunological response, but no TSO dose showed a clinically relevant effect over placebo for the induction of clinical remission (CD Activity Index < 150) or response[48].

In UC, the first study was sponsored by the New York University School of Medicine, and the second by the National Institute of Allergy and Infectious Diseases. Both were terminated due to a small sample size and because it was not possible to draw meaningful conclusions. MUCUS (NCT01433471), a randomized, double-blind, placebo-controlled crossover study, was conceived to examine mucosal immunity after therapy with 2500 eggs by mouth every 2 wk for 12 wk. Primary outcomes were designed to better understand the mechanism of action of TSO on the intestinal mucosa and secondary outcomes were to bring about changes in the Mayo Score and in the Simple Clinical Colitis Activity Index.

A second, more controversial approach, was the use of N. americanus. Croese et al[49] showed that 7 of 9 patients with CD infected with 25-50 larvae followed over 20 wk experienced an improved CD activity index, while the other 2 worsened. There were no search results for interventional studies regarding the use of Strongyloides, Ascaris, Ancylostoma, Wuchereria, Onchocerca, Toxocara or Enterobius in CD or UC on Clinicaltrials.gov.

Evidence of helminth therapy in celiac disease

There are few studies examining the use of helminths in celiac disease, most of which with small samples. McSorley et al[50] and Daveson et al[51] examined 20 celiac patients followed by wheat challenge after 20 wk exposed to 5-10 larvae of N. americanus, compared to placebo, at Princess Alexandra Hospital, in Brisbane, Australia. The dose was well tolerated and analysis showed reduced gamma interferon and interleukin-17A in duodenal biopsies. No difference in symptoms was observed.

Another Australian clinical trial, NaCeD study (NCT016619330), evaluated the desensitization and gluten tolerance of 12 diet-managed celiac patients. They were previously infected with N. americanus and exposed to small incremental doses of gluten, in the form of pasta, over 12 wk. The mucosal histopathology before and after gluten challenge was examined. There were no significant differences in terms of duodenal villus height and crypt depth ratio and intraepithelial lymphocyte count.

Another clinical trial (NCT02754609) was registered in 2016 by James Cook University in Queensland, Australia, on Clinicaltrials.gov. This trial aims to be a phase 1b multicenter, multinational, randomized, double-blind, placebo-controlled clinical trial with a single-blind arm and an open label extension phase. The objective is to evaluate the safety and predictability of escalating gluten consumption to activate celiac disease. The cohort with diet-managed disease will be treated with placebo or with low- and medium-dose hookworm inocula. The primary outcome is to measure the difference in duodenal villus height and crypt depth ratio between baseline (week 2) and week 42.

There were no search results for interventional studies about Trichuris, Strongyloides, Ascaris, Ancylostoma, Wuchereria, Onchocerca, Toxocara or Enterobius use in the treatment of celiac disease on Clinicaltrials.gov.

Other uses for helminth therapy

There are other studies examining the role of helminth therapy in allergy, atopy and asthma, with conflicting results. The biggest problem seems to be that these studies proved that preventing allergic reactivity is possible, but only a handful have reported the ability to impact an already established process. In addition to allergy, a number of clinical trials are currently registered for the use of TSO in patients with multiple sclerosis[52], psoriasis, autism and rheumatoid arthritis[37], and for the use of N. americanus in patients with multiple sclerosis[35].

Helminth products as possible new drugs

Helminths are complex organisms that have a variety of immunomodulatory substances, such as lipids, carbohydrates and proteins, and jointly defined excretory-secretory products (ES). The identification of helminth products that can be used as biologicals in place of whole parasites is an engaging area of research. The ES-62 glycoprotein from the filarial nematode Acanthocheilonema vitae is one of the most studied compounds and is capable of promoting a Th2 response, inhibiting Th1 and Th17. Animal studies have demonstrated the ability of various ES products to inhibit intestinal inflammation in colitis models. These studies suggest a potential way for discovering new drugs for IBD. Concerns about antigenicity and safety need to be clarified prior to clinical testing[53].

Most published studies focus on the use of nematodes and their products in the treatment of intestinal disease. Unlike most studies, there is an ongoing multicenter phase 2 clinical trial, in the recruiting phase, sponsored by the University Hospital, Lille, France, named ACROHNEM (NCT02281916). It is designed to assess safety and tolerability of P28GST (protein 28 Kd glutathion S transferase), aiming to control inflammation in moderate CD, before or after intestinal resection surgery. P28GST is a parasite enzyme molecule from Schistosoma with potent immunogenic and anti-oxidant properties. Based on the experimental evidence of its anti-inflammatory properties, investigators hypothesized that the administration of P28GST could protect against recurrence after intestinal resection surgery in CD. To carry out this study, 24 moderate CD patients will be enrolled. Patients with moderate CD will be included after intestinal resection surgery. Drug therapy will consist of three injections of 100 µg of P28GST for 3 mo (one injection per month). The main objective of this study is to assess safety and tolerability in a 1-year follow-up. Secondary objectives are to control immunologic and inflammatory blood and tissue markers and evaluate clinical recurrence as assessed by CDAI (CD Activity Index).

CONCLUSION

The intestinal microbiota is responsible for shaping the human immune system, and the composition of the microbiome can alter and deviate specific host immune responses. Although much has been written about bacteria, we cannot forget that other organisms, such as the helminths, may possibly play an important role in maintaining a “healthy intestinal community”[54].

Mouse models[55] and human cross-sectional studies have shown that chronic helminth infections exert immunomodulatory activity and are able to regulate the host immune response, providing a potential beneficial action on autoimmune and inflammatory disorders in humans, such as IBD, celiac disease, asthma, atopy, allergy, multiple sclerosis, psoriasis, autism and rheumatoid arthritis[37].

We have some evidence about the safety and tolerance of helminth use, but evidence about the impact on various intestinal diseases is lacking. We need more clinical studies with larger samples, longer follow-ups and standardized doses of helminths and helminth products. Some questions remain to be investigated regarding the use of helminths in intestinal disease, such as the importance of the particular species of helminths used; appropriate dosing regimens (low or high); optimal timing of treatment (before the onset of disease, in acute or chronic disease, or at younger ages); the role of host genetics, diet and environment, and elucidation of the exact mechanisms of protective effect.

In regard to the species of helminth, we believe that the majority of the studies had negative results because of the use of T. suis. This pig whipworm induces a less intense and persistent inflammatory response, although Williams et al[56] verified that T. suis can mature to adult size and reproduce in humans. That is why we see S. stercoralis as a more potentially useful nematode, as it has proven to significantly diminish the intestinal permeability in humans[23], altering the interleukin profile in a more systemic way[42]. The prolonged interaction between S. stercoralis and its host induces a greater immunomodulatory action. Regarding the appropriate dose and duration of treatment, we have little comprehension of how much and how long is required to exert a significant and beneficial effect; therefore, safety concerns limit the dose that can be applied.

One important challenge is the high polymorphism of the human species, which reacts in a spectral manner to helminth infection. The genetic profile of each individual alters this response. In this context, the identification of helminth-derived anti-inflammatory molecular mediators may be a better and promising approach, since it replicates the benefits without the detriments[57]. There are many challenges with this method, such as the selection of a substance with a good safety profile and low antigenicity that is easily produced and that has a significant impact on clinical trials.

Footnotes

Manuscript source: Invited manuscript

Specialty type: World Journal of Gastroenterology

Country of origin: Brazil

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): E

P- Reviewer: Ferrante A, Garcia-Olmo D, Nagata T, Yankee T S- Editor: Qi Y L- Editor: A E- Editor: Huang Y

References
1.  Kraehenbuhl JP, Pringault E, Neutra MR. Review article: Intestinal epithelia and barrier functions. Aliment Pharmacol Ther. 1997;11 Suppl 3:3-8; discussion 8-9.  [PubMed]  [DOI]
2.  Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am. 1995;24:475-507.  [PubMed]  [DOI]
3.  Ainsworth M, Eriksen J, Rasmussen JW, Schaffalitzky de Muckadell OB. Intestinal permeability of 51Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn’s disease and their healthy relatives. Scand J Gastroenterol. 1989;24:993-998.  [PubMed]  [DOI]
4.  Bjarnason I, O’Morain C, Levi AJ, Peters TJ. Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology. 1983;85:318-322.  [PubMed]  [DOI]
5.  Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn’s disease and their relatives. A possible etiologic factor. Ann Intern Med. 1986;105:883-885.  [PubMed]  [DOI]
6.  Hollander D. Crohn’s disease--a permeability disorder of the tight junction? Gut. 1988;29:1621-1624.  [PubMed]  [DOI]
7.  Hollander D. The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn’s disease. Scand J Gastroenterol. 1992;27:721-726.  [PubMed]  [DOI]
8.  Jenkins RT, Jones DB, Goodacre RL, Collins SM, Coates G, Hunt RH, Bienenstock J. Reversibility of increased intestinal permeability to 51Cr-EDTA in patients with gastrointestinal inflammatory diseases. Am J Gastroenterol. 1987;82:1159-1164.  [PubMed]  [DOI]
9.  Jenkins RT, Ramage JK, Jones DB, Collins SM, Goodacre RL, Hunt RH. Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med. 1988;11:151-155.  [PubMed]  [DOI]
10.  O'Morain CA, Abelow AC, Chervu LR, Fleischner GM, Das KM. Chromium 51-ethylenediaminetetraacetate test: a useful test in the assessment of inflammatory bowel disease. J Lab Clin Med. 1986;108:430-435.  [PubMed]  [DOI]
11.  Zuckerman MJ, Watts MT. Intestinal permeability to 51Cr-ethylenediaminetetraacetate in patients with ulcerative colitis. Am J Gastroenterol. 1993;88:1978-1979.  [PubMed]  [DOI]
12.  Forget P, Sodoyez-Goffaux F, Zappitelli A. Permeability of the small intestine to [51Cr]EDTA in children with acute gastroenteritis or eczema. J Pediatr Gastroenterol Nutr. 1985;4:393-396.  [PubMed]  [DOI]
13.  Bjarnason I, Marsh MN, Price A, Levi AJ, Peters TJ. Intestinal permeability in patients with coeliac disease and dermatitis herpetiformis. Gut. 1985;26:1214-1219.  [PubMed]  [DOI]
14.  Escobar H, Perdomo M, Vasconez F, Camarero C, del Olmo MT, Suárez L. Intestinal permeability to 51Cr-EDTA and orocecal transit time in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1992;14:204-207.  [PubMed]  [DOI]
15.  Leclercq-Foucart J, Forget P, Sodoyez-Goffaux F, Zappitelli A. Intestinal permeability to [51Cr]EDTA in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 1986;5:384-387.  [PubMed]  [DOI]
16.  Bjarnason I, Peters TJ, Wise RJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet. 1984;1:179-182.  [PubMed]  [DOI]
17.  Aabakken L, Osnes M. 51Cr-ethylenediaminetetraacetic acid absorption test. Effects of naproxen, a non-steroidal, antiinflammatory drug. Scand J Gastroenterol. 1990;25:917-924.  [PubMed]  [DOI]
18.  Bjarnason I, Williams P, So A, Zanelli GD, Levi AJ, Gumpel JM, Peters TJ, Ansell B. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984;2:1171-1174.  [PubMed]  [DOI]
19.  Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut. 1986;27:1292-1297.  [PubMed]  [DOI]
20.  Jenkins AP, Trew DR, Crump BJ, Nukajam WS, Foley JA, Menzies IS, Creamer B. Do non-steroidal anti-inflammatory drugs increase colonic permeability? Gut. 1991;32:66-69.  [PubMed]  [DOI]
21.  Zuckerman MJ, Watts MT, Bhatt BD, Ho H. Intestinal permeability to [51Cr]EDTA in infectious diarrhea. Dig Dis Sci. 1993;38:1651-1657.  [PubMed]  [DOI]
22.  Zuckerman MJ, Watts MT, Ho H, Meriano FV. Blastocystis hominis infection and intestinal injury. Am J Med Sci. 1994;308:96-101.  [PubMed]  [DOI]
23.  Werneck-Silva AL, Sipahi AM, Damião AO, Buchpigue CA, Iriya K, Laudanna AA. Intestinal permeability in strongyloidiasis. Braz J Med Biol Res. 2001;34:353-357.  [PubMed]  [DOI]
24.  de PAOLA, DIAS LB, da SILVA J. Enteritis due to Strongyloides stercoralis. A report of 5 fatal cases. Am J Dig Dis. 1962;7:1086-1098.  [PubMed]  [DOI]
25.  Viney ME, Lok JB. Strongyloides spp. WormBook. 2007;1-15.  [PubMed]  [DOI]
26.  Cook GC. Strongyloides stercoralis hyperinfection syndrome: how often is it missed? Q J Med. 1987;64:625-629.  [PubMed]  [DOI]
27.  Purtilo DT, Meyers WM, Connor DH. Fatal strongyloidiasis in immunosuppressed patients. Am J Med. 1974;56:488-493.  [PubMed]  [DOI]
28.  Igra-Siegman Y, Kapila R, Sen P, Kaminski ZC, Louria DB. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis. 1981;3:397-407.  [PubMed]  [DOI]
29.  Gerrard JW, Geddes CA, Reggin PL, Gerrard CD, Horne S. Serum IgE levels in white and metis communities in Saskatchewan. Ann Allergy. 1976;37:91-100.  [PubMed]  [DOI]
30.  Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259-1260.  [PubMed]  [DOI]
31.  von Mutius E, Vercelli D. Farm living: effects on childhood asthma and allergy. Nat Rev Immunol. 2010;10:861-868.  [PubMed]  [DOI]
32.  Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, Williams H; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733-743.  [PubMed]  [DOI]
33.  Nicolaou N, Siddique N, Custovic A. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization. Allergy. 2005;60:1357-1360.  [PubMed]  [DOI]
34.  Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? Trends Microbiol. 2004;12:562-568.  [PubMed]  [DOI]
35.  Aoyama H, Hirata T, Sakugawa H, Watanabe T, Miyagi S, Maeshiro T, Chinen T, Kawane M, Zaha O, Nakayoshi T. An inverse relationship between autoimmune liver diseases and Strongyloides stercoralis infection. Am J Trop Med Hyg. 2007;76:972-976.  [PubMed]  [DOI]
36.  Wammes LJ, Mpairwe H, Elliott AM, Yazdanbakhsh M. Helminth therapy or elimination: epidemiological, immunological, and clinical considerations. Lancet Infect Dis. 2014;14:1150-1162.  [PubMed]  [DOI]
37.  Helmby H. Human helminth therapy to treat inflammatory disorders - where do we stand? BMC Immunol. 2015;16:12.  [PubMed]  [DOI]
38.  Vukman KV, Lalor R, Aldridge A, O’Neill SM. Mast cells: new therapeutic target in helminth immune modulation. Parasite Immunol. 2016;38:45-52.  [PubMed]  [DOI]
39.  Grencis RK, Humphreys NE, Bancroft AJ. Immunity to gastrointestinal nematodes: mechanisms and myths. Immunol Rev. 2014;260:183-205.  [PubMed]  [DOI]
40.  Allen JE, Wynn TA. Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathog. 2011;7:e1002003.  [PubMed]  [DOI]
41.  Schopf LR, Hoffmann KF, Cheever AW, Urban JF Jr, Wynn TA. IL-10 is critical for host resistance and survival during gastrointestinal helminth infection. J Immunol. 2002;168:2383-2392.  [PubMed]  [DOI]
42.  Anuradha R, Munisankar S, Dolla C, Kumaran P, Nutman TB, Babu S. Parasite Antigen-Specific Regulation of Th1, Th2, and Th17 Responses in Strongyloides stercoralis Infection. J Immunol. 2015;195:2241-2250.  [PubMed]  [DOI]
43.  Anuradha R, Munisankar S, Bhootra Y, Jagannathan J, Dolla C, Kumaran P, Shen K, Nutman TB, Babu S. Systemic Cytokine Profiles in Strongyloides stercoralis Infection and Alterations following Treatment. Infect Immun. 2015;84:425-431.  [PubMed]  [DOI]
44.  Summers RW, Elliott DE, Qadir K, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2003;98:2034-2041.  [PubMed]  [DOI]
45.  Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn’s disease. Gut. 2005;54:87-90.  [PubMed]  [DOI]
46.  Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005;128:825-832.  [PubMed]  [DOI]
47.  Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;38:255-263.  [PubMed]  [DOI]
48.  Schölmerich J, Fellermann K, Seibold FW, Rogler G, Langhorst J, Howaldt S, Novacek G, Petersen AM, Bachmann O, Matthes H. A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn’s Disease. J Crohns Colitis. 2017;11:390-399.  [PubMed]  [DOI]
49.  Croese J, O’neil J, Masson J, Cooke S, Melrose W, Pritchard D, Speare R. A proof of concept study establishing Necator americanus in Crohn’s patients and reservoir donors. Gut. 2006;55:136-137.  [PubMed]  [DOI]
50.  McSorley HJ, Gaze S, Daveson J, Jones D, Anderson RP, Clouston A, Ruyssers NE, Speare R, McCarthy JS, Engwerda CR. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One. 2011;6:e24092.  [PubMed]  [DOI]
51.  Daveson AJ, Jones DM, Gaze S, McSorley H, Clouston A, Pascoe A, Cooke S, Speare R, Macdonald GA, Anderson R. Effect of hookworm infection on wheat challenge in celiac disease--a randomised double-blinded placebo controlled trial. PLoS One. 2011;6:e17366.  [PubMed]  [DOI]
52.  Benzel F, Erdur H, Kohler S, Frentsch M, Thiel A, Harms L, Wandinger KP, Rosche B. Immune monitoring of Trichuris suis egg therapy in multiple sclerosis patients. J Helminthol. 2012;86:339-347.  [PubMed]  [DOI]
53.  Harnett W. Secretory products of helminth parasites as immunomodulators. Mol Biochem Parasitol. 2014;195:130-136.  [PubMed]  [DOI]
54.  Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313-323.  [PubMed]  [DOI]
55.  Helmby H. Helminths and our immune system: friend or foe? Parasitol Int. 2009;58:121-127.  [PubMed]  [DOI]
56.  Williams AR, Dige A, Rasmussen TK, Hvas CL, Dahlerup JF, Iversen L, Stensvold CR, Agnholt J, Nejsum P. Immune responses and parasitological observations induced during probiotic treatment with medicinal Trichuris suis ova in a healthy volunteer. Immunol Lett. 2017;188:32-37.  [PubMed]  [DOI]
57.  Maizels RM. Parasitic helminth infections and the control of human allergic and autoimmune disorders. Clin Microbiol Infect. 2016;22:481-486.  [PubMed]  [DOI]